SCHEDULE: Intracoastal Capital Acquires Stake in Silexion Therapeutics

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, have reported beneficial ownership of 4.99% of Silexion Therapeutics Corp. ordinary shares.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the 'Reporting Persons') have filed a Schedule 13G.
• The filing indicates beneficial ownership of 286,866 ordinary shares of Silexion Therapeutics Corp., representing 4.99% of the class.
• This ownership level is below the 5% threshold that would require a more detailed Schedule 13D filing.
• The reporting persons acquired these shares through a combination of direct holdings and exercisable warrants, subject to blocker provisions.
• The effective date for this ownership reporting is August 18, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, primarily due to the reporting persons' acquisition of a significant stake below the 5% threshold, indicating strategic interest without triggering immediate disclosure obligations for control changes.

Positives

• The Reporting Persons have acquired a substantial stake in Silexion Therapeutics Corp., demonstrating confidence in the company.
• The ownership is reported at 4.99%, strategically staying below the 5% threshold that would trigger a Schedule 13D filing, suggesting a non-control-oriented investment at this stage.
• The filing details the complex warrant structures and blocker provisions, providing transparency on how the ownership stake was achieved and is managed.

Negatives

• The filing does not provide specific financial performance data for Silexion Therapeutics Corp., making it difficult to assess the company's underlying health.
• The reliance on warrants and potential for future exercise introduces a degree of uncertainty regarding the final ownership structure and potential market impact.

Risks

• The blocker provisions in the warrants limit the Reporting Persons' ability to exercise them beyond certain ownership thresholds (4.99% or 9.99%), potentially capping their influence or investment size.
• Future exercise of warrants, even with blocker provisions, could lead to dilution for existing shareholders if new shares are issued.
• The filing does not detail the specific business strategy or financial performance of Silexion Therapeutics Corp., making it difficult to assess the inherent risks of the investment.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Silexion Therapeutics Corp. The future outlook for the Reporting Persons' stake is dependent on the exercise of warrants and the company's performance, subject to blocker provisions.

Management Comments

• The Reporting Persons certify that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual investors acquiring stakes in public companies. The 4.99% ownership level is a strategic maneuver to avoid the more stringent disclosure requirements of a Schedule 13D, which is typically filed when beneficial ownership exceeds 5% and suggests a passive investment approach rather than an attempt to gain control.

Stakeholder Impact

• Shareholders: The acquisition of a significant stake by the Reporting Persons may signal investor confidence, but the potential exercise of warrants could lead to dilution.
• Management: The Reporting Persons' stake is below the threshold that would typically trigger concerns about control changes, allowing management to continue operations without immediate pressure.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• The Reporting Persons will continue to monitor their beneficial ownership levels and may file amendments to this Schedule 13G if circumstances change.
• Silexion Therapeutics Corp. will continue its business operations, the performance of which will impact the value of the Reporting Persons' investment.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Intracoastal Capital LLC, Silexion Therapeutics Corp., Ordinary Shares, Warrants, Blocker Provision, SEC Filing